Search Results

You are looking at 1 - 2 of 2 items for

  • Author or Editor: Peter Heidmann x
  • Refine by Access: All Content x
Clear All Modify Search

Abstract

Zoonoses, diseases that can be transmitted from animals to humans, can pose serious health risks to immunocompromised people. Although pets can carry zoonoses, owning and caring for animals can benefit human health. Information exists about preventing transmission of zoonoses, but not all physiCians and veterinarians provide adequate and accurate information to immunocompromised pet owners.1 This disease prevention/health promotion project provides physicians and veterinarians with information, created specifically to share with patients and clients, about the health risks and benefits of pet ownership. Further, “Healthy Pets, Healthy People” encourages communication between veterinarians, physicians, clients, and patients and can serve as a model program for a nationwide effort to aid health professionals in making recommendations about pet ownership for immunocompromised people.

Free access
in Journal of the American Veterinary Medical Association

Abstract

Objective—To determine whether ϵ-aminocaproic acid (EACA) administered IV affects hemostasis and fibrinolysis in clinically normal horses and ponies.

Animals—20 clinically normal adult horses and ponies.

Procedures—Blood samples were collected 24 hours before (baseline) and 1 and 5 hours after IV administration of a low dose (30 mg/kg) or high dose (100 mg/kg) of EACA. Platelet count, fibrinogen concentration, prothrombin time, partial thromboplastin time (PTT), D-dimer concentration, α2-antiplasmin activity, and thrombin-antithrombin complex concentration were measured. Values at 1 and 5 hours were compared with baseline values.

Results—1 hour after administration of a low dose of EACA, mean fibrinogen concentration was significantly lower than baseline concentration. Mean PTT was significantly shorter than the baseline value 5 hours after administration of a low dose of EACA. One hour after administration of 100 mg of EACA/kg, mean α2-antiplasmin activity was significantly higher than baseline activity. Mean fibrinogen concentration was significantly lower than baseline concentration 1 and 5 hours after administration of a high dose of EACA. Mean PTT was significantly shorter than the baseline value 5 hours after administration of a high dose of EACA.

Conclusions and Clinical Relevance—IV administration of 30 and 100mg of EACA/kg to clinically normal horses significantly modified some laboratory measures of hemostasis, consistent with its known antifibrinolytic effects. Although enhanced clot maintenance and diminished bleeding were not directly assessed, the clinical use of EACA may benefit some patients. ( Am J Vet Res 2005;66:313–318)

Full access
in American Journal of Veterinary Research